115 related articles for article (PubMed ID: 27976416)
21. Delayed viral suppression during antiviral therapy is associated with increased hepatocellular carcinoma rates in HBeAg-positive high viral load chronic hepatitis B.
Nam JY; Chang Y; Cho H; Kang SH; Cho YY; Cho EJ; Lee JH; Yu SJ; Yoon JH; Kim YJ
J Viral Hepat; 2018 May; 25(5):552-560. PubMed ID: 29194870
[TBL] [Abstract][Full Text] [Related]
22. Long-term safety of oral nucleos(t)ide analogs for patients with chronic hepatitis B: A cohort study of 53,500 subjects.
Wong GL; Tse YK; Wong VW; Yip TC; Tsoi KK; Chan HL
Hepatology; 2015 Sep; 62(3):684-93. PubMed ID: 25973979
[TBL] [Abstract][Full Text] [Related]
23. Results of a retrospective database analysis of drug utilization and costs for treatment of chronic hepatitis B virus infection in the northern Netherlands between 2000 and 2006.
Tu HA; Bos JH; Woerdenbag HJ; Visser ST; Wilschut JC; van Assen S; de Jong-van den Berg LT; Postma MJ
Clin Ther; 2010 Jan; 32(1):133-44. PubMed ID: 20171419
[TBL] [Abstract][Full Text] [Related]
24. Hepatitis B e antigen-negative chronic hepatitis B in Hong Kong.
Chan HL; Leung NW; Hussain M; Wong ML; Lok AS
Hepatology; 2000 Mar; 31(3):763-8. PubMed ID: 10706570
[TBL] [Abstract][Full Text] [Related]
25. Soluble CD163 and mannose receptor associate with chronic hepatitis B activity and fibrosis and decline with treatment.
Laursen TL; Wong GL; Kazankov K; Sandahl T; Møller HJ; Hamilton-Dutoit S; George J; Chan HL; Grønbaek H
J Gastroenterol Hepatol; 2018 Feb; 33(2):484-491. PubMed ID: 28618015
[TBL] [Abstract][Full Text] [Related]
26. Entecavir: a new nucleoside analogue for the treatment of chronic hepatitis B.
Rivkin A
Drugs Today (Barc); 2007 Apr; 43(4):201-20. PubMed ID: 17460784
[TBL] [Abstract][Full Text] [Related]
27. Longitudinal profiles of highly sensitive hepatitis B surface antigen levels: re-evaluation of HBsAg seroclearance.
Seto WK; Tanaka Y; Wong DK; Shinkai N; Cheung KS; Liu KS; Fung J; Lai CL; Yuen MF
Liver Int; 2016 May; 36(5):642-50. PubMed ID: 26474013
[TBL] [Abstract][Full Text] [Related]
28. Quantitative hepatitis B surface antigen analysis in hepatitis B e antigen-positive nucleoside-naive patients treated with entecavir.
Gish RG; Chang TT; Lai CL; de Man RA; Gadano A; Llamoso C; Tang H
Antivir Ther; 2013; 18(5):691-8. PubMed ID: 23510982
[TBL] [Abstract][Full Text] [Related]
29. Oral nucleos(t)ide analogues reduce recurrence and death in chronic hepatitis B-related hepatocellular carcinoma.
Wong GL; Tse YK; Chan HL; Yip TC; Tsoi KK; Wong VW
Aliment Pharmacol Ther; 2016 Apr; 43(7):802-13. PubMed ID: 26843444
[TBL] [Abstract][Full Text] [Related]
30. Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment.
Wong GL; Chan HL; Chan HY; Tse PC; Tse YK; Mak CW; Lee SK; Ip ZM; Lam AT; Iu HW; Leung JM; Wong VW
Gastroenterology; 2013 May; 144(5):933-44. PubMed ID: 23415803
[TBL] [Abstract][Full Text] [Related]
31. On-treatment low serum HBV RNA level predicts initial virological response in chronic hepatitis B patients receiving nucleoside analogue therapy.
Huang YW; Takahashi S; Tsuge M; Chen CL; Wang TC; Abe H; Hu JT; Chen DS; Yang SS; Chayama K; Kao JH
Antivir Ther; 2015; 20(4):369-75. PubMed ID: 24739420
[TBL] [Abstract][Full Text] [Related]
32. Tenofovir disoproxil fumarate monotherapy for nucleos(t)ide analogue-naïve and nucleos(t)ide analogue-experienced chronic hepatitis B patients.
Jung SK; Kim KA; Ha SY; Lee HK; Kim YD; Lee BH; Paik WH; Kim JW; Bae WK; Kim NH; Lee JS; Jwa YJ
Clin Mol Hepatol; 2015 Mar; 21(1):41-8. PubMed ID: 25834801
[TBL] [Abstract][Full Text] [Related]
33. A critical evaluation of the preventive effect of antiviral therapy on the development of hepatocellular carcinoma in patients with chronic hepatitis C or B: a novel approach by using meta-regression.
Shen YC; Hsu C; Cheng CC; Hu FC; Cheng AL
Oncology; 2012; 82(5):275-89. PubMed ID: 22555181
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of switching from adefovir to tenofovir in chronic hepatitis B patients who exhibit suboptimal responses to adefovir-based combination rescue therapy due to resistance to nucleoside analogues (SATIS study).
Lee HW; Park JY; Kim BK; Kim MY; Lee JI; Kim YS; Yoon KT; Han KH; Ahn SH
Clin Mol Hepatol; 2016 Dec; 22(4):443-449. PubMed ID: 27880997
[TBL] [Abstract][Full Text] [Related]
35. Changes in liver histology as a "surrogate" end point of antiviral therapy for chronic HBV can predict progression to liver complications.
Hui CK; Leung N; Shek WH; Zhang HY; Luk JM; Poon RT; Lo CM; Fan ST; Lau GK;
J Clin Gastroenterol; 2008; 42(5):533-8. PubMed ID: 18344885
[TBL] [Abstract][Full Text] [Related]
36. Individualized treatment of HBeAg-negative chronic hepatitis B using pegylated interferon-α2a as first-line and week-12 HBV DNA/HBsAg stopping rule: a cost-effectiveness analysis.
Iannazzo S; Coco B; Brunetto MR; Rossetti F; Caputo A; Latour A; Espinos B; Bonino F
Antivir Ther; 2013; 18(4):623-33. PubMed ID: 23486701
[TBL] [Abstract][Full Text] [Related]
37. Long-term outcomes of entecavir monotherapy for chronic hepatitis B after liver transplantation: Results up to 8 years.
Fung J; Wong T; Chok K; Chan A; Cheung TT; Dai JW; Sin SL; Ma KW; Ng K; Ng KT; Seto WK; Lai CL; Yuen MF; Lo CM
Hepatology; 2017 Oct; 66(4):1036-1044. PubMed ID: 28370215
[TBL] [Abstract][Full Text] [Related]
38. Hepatitis B surface antigen seroclearance during nucleoside analogue therapy: surface antigen kinetics, outcomes, and durability.
Seto WK; Cheung KS; Wong DK; Huang FY; Fung J; Liu KS; Lai CL; Yuen MF
J Gastroenterol; 2016 May; 51(5):487-95. PubMed ID: 26446756
[TBL] [Abstract][Full Text] [Related]
39. Monotherapy for hepatitis B infection: a review of treatment options.
Ozaras R; Khodor H; Yetim N; Unal UK; Demirhan YE; Gultekin G; Isal B
Expert Rev Anti Infect Ther; 2015; 13(12):1457-68. PubMed ID: 26414781
[TBL] [Abstract][Full Text] [Related]
40. Benefits of long-term therapy with nucleos(t)ide analogues in treatment-naïve patients with chronic hepatitis B.
Wei L; Kao JH
Curr Med Res Opin; 2017 Mar; 33(3):495-504. PubMed ID: 27882776
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
